Roxadustat for CKD Anemia - Starting the Jigsaw Puzzle, What Will the Finished Picture Show?
作者信息
Winkelmayer Wolfgang C, Walther Carl P
机构信息
Department of Medicine, Section of Nephrology, Baylor College of Medicine, Houston, Texas, USA.
出版信息
Kidney Int Rep. 2021 Feb 4;6(3):559-561. doi: 10.1016/j.ekir.2021.01.035. eCollection 2021 Mar.
Abstract
摘要
相似文献
1
Roxadustat for CKD Anemia - Starting the Jigsaw Puzzle, What Will the Finished Picture Show?罗沙司他用于慢性肾脏病贫血——开始拼拼图，完成后的画面会是怎样？
Kidney Int Rep. 2021 Feb 4;6(3):559-561. doi: 10.1016/j.ekir.2021.01.035. eCollection 2021 Mar.
2
Retraction notice to "Roxadustat for CKD Anemia - Starting the Jigsaw Puzzle, What Will the Finished Picture Show?" 2021;6:559-561.《罗沙司他用于慢性肾脏病贫血——拼图开始，最终图景如何？》撤稿通知 2021 年；6:559 - 561 。
Kidney Int Rep. 2022 Feb 5;7(3):665. doi: 10.1016/j.ekir.2022.01.1070. eCollection 2022 Mar.
3
Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.罗沙司他（FG-4592）治疗透析依赖（DD）和非透析依赖（NDD）慢性肾脏病患者的贫血：系统评价和荟萃分析。
Pharmacol Res. 2020 May;155:104747. doi: 10.1016/j.phrs.2020.104747. Epub 2020 Mar 17.
4
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.口服低氧诱导因子脯氨酰羟化酶抑制剂罗沙司他（FG-4592）用于治疗慢性肾脏病患者的贫血
Clin J Am Soc Nephrol. 2016 Jun 6;11(6):982-991. doi: 10.2215/CJN.06890615. Epub 2016 Apr 19.
5
Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.罗沙司他治疗非透析依赖性慢性肾脏病患者贫血的疗效和心血管安全性：三项随机临床试验的汇总结果。
Clin J Am Soc Nephrol. 2021 Aug;16(8):1190-1200. doi: 10.2215/CJN.16191020.
6
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.罗沙司他治疗非透析和透析依赖性慢性肾脏病贫血患者的铁状态变化。
Kidney360. 2022 Jun 29;3(9):1511-1528. doi: 10.34067/KID.0001442022. eCollection 2022 Sep 29.
7
Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.罗沙司他治疗慢性肾脏病患者贫血的安全性和有效性：一项荟萃分析和试验序贯分析
Front Med (Lausanne). 2021 Aug 31;8:724456. doi: 10.3389/fmed.2021.724456. eCollection 2021.
8
Treatment of Renal Anemia with Roxadustat: Advantages and Achievement.罗沙司他治疗肾性贫血：优势与成效
Kidney Dis (Basel). 2020 Mar;6(2):65-73. doi: 10.1159/000504850. Epub 2020 Jan 10.
9
Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?脯氨酰羟化酶抑制剂罗沙司他治疗慢性肾脏病患者贫血：未来的方向？
Int J Environ Res Public Health. 2021 Feb 8;18(4):1612. doi: 10.3390/ijerph18041612.
10
Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease.开发一种健康经济模型，以评估罗沙司他治疗非透析依赖性慢性肾脏病相关贫血的成本效益。
J Med Econ. 2023 Jan-Dec;26(1):1250-1260. doi: 10.1080/13696998.2023.2263263. Epub 2023 Oct 10.
引用本文的文献
1
Treatment of Anemia in Kidney Disease: Beyond Erythropoietin.肾病贫血的治疗：超越促红细胞生成素
Kidney Int Rep. 2021 Jun 9;6(10):2540-2553. doi: 10.1016/j.ekir.2021.05.028. eCollection 2021 Oct.
2
Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle.用于治疗慢性肾脏病贫血的缺氧诱导因子脯氨酰羟化酶抑制剂：拼图的其他部分
Kidney Int Rep. 2021 Jun 23;6(7):1751-1754. doi: 10.1016/j.ekir.2021.05.017. eCollection 2021 Jul.
本文引用的文献
1
Roxadustat for CKD-related Anemia in Non-dialysis Patients.罗沙司他用于非透析患者的慢性肾脏病相关贫血
Kidney Int Rep. 2020 Dec 5;6(3):624-635. doi: 10.1016/j.ekir.2020.11.034. eCollection 2021 Mar.
2
Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.罗沙司他用于透析起始的肾衰竭患者贫血治疗的汇总分析
Kidney Int Rep. 2020 Dec 24;6(3):613-623. doi: 10.1016/j.ekir.2020.12.018. eCollection 2021 Mar.
3
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.罗沙司他治疗未接受透析的肾病患者的贫血。
N Engl J Med. 2019 Sep 12;381(11):1001-1010. doi: 10.1056/NEJMoa1813599. Epub 2019 Jul 24.
4
Chapter 2: Use of iron to treat anemia in CKD.第2章：铁剂在慢性肾脏病贫血治疗中的应用。
Kidney Int Suppl (2011). 2012 Aug;2(4):292-298. doi: 10.1038/kisup.2012.34.
5
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.阿法达贝泊汀治疗2型糖尿病和慢性肾病的一项试验。
N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.
6
Correction of anemia with epoetin alfa in chronic kidney disease.慢性肾脏病中使用促红细胞生成素α纠正贫血
N Engl J Med. 2006 Nov 16;355(20):2085-98. doi: 10.1056/NEJMoa065485.
7
Normalization of hemoglobin level in patients with chronic kidney disease and anemia.慢性肾脏病合并贫血患者血红蛋白水平的正常化。
N Engl J Med. 2006 Nov 16;355(20):2071-84. doi: 10.1056/NEJMoa062276.
8
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.接受血液透析和促红细胞生成素治疗的心脏病患者中，正常血细胞比容值与低血细胞比容值的影响比较
N Engl J Med. 1998 Aug 27;339(9):584-90. doi: 10.1056/NEJM199808273390903.
Zotero 插件